Royal Bank Of Canada Medicenna Therapeutics Corp. Transaction History

Royal Bank Of Canada

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$0.28 - $0.51 $15,451 - $28,144	55,185 Added 46.47%	173,945 $52,000
Q2 2023 Aug 14, 2023	SELL	$0.44 - $0.82 $1,921 - $3,581	-4,368 Reduced 3.55%	118,760 $57,000
Q1 2023 May 15, 2023	BUY	$0.5 - $0.78 $2,439 - $3,804	4,878 Added 4.13%	123,128 $77,000
Q4 2022 Feb 14, 2023	BUY	$0.4 - $0.68 $45,000 - $76,500	112,501 Added 1956.88%	118,250 $54,000
Q3 2022 Nov 14, 2022	BUY	$0.83 - $1.78 $351 - $754	424 Added 7.96%	5,749 $5,000
Q2 2022 Aug 15, 2022	SELL	$0.79 - $1.32 $5,139 - $8,587	-6,506 Reduced 54.99%	5,325 $6,000
Q1 2022 May 16, 2022	BUY	$1.26 - $1.92 $1,232 - $1,877	978 Added 9.01%	11,831 $15,000
Q4 2021 Feb 14, 2022	SELL	$1.53 - $2.85 $57,277 - $106,692	-37,436 Reduced 77.52%	10,853 $18,000
Q3 2021 Nov 15, 2021	BUY	$1.91 - $3.05 $61,715 - $98,551	32,312 Added 202.24%	48,289 $134,000
Q2 2021 Aug 16, 2021	BUY	$2.97 - $4.28 $47,451 - $68,381	15,977 New	15,977 $48,000

863K

Ticker MDNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,637,504
Market Cap $21.6M
Description
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.